nach oben

Langenbeck's Archives of Surgery

Erschienen in:

01.04.2012 | Review Article

Chemoprevention of pancreatic cancer—one step closer

verfasst von: Volker Fendrich

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Since for pancreatic cancer the mortality rate approaches the incidence rate with only 1–4% of all patients surviving 5 years, it would be would be of great value to provide chemopreventive treatment for high-risk individuals.

Discussion

The preclinical study of pancreatic intraepithelial neoplasia (PanINs) has recently been made possible by the generation of genetically modified animal models, which recapitulate human PanINs and invasive pancreatic cancer on a genetic and histomorphologic level. Very recently, several groups have reported first evidence of chemoprevention of pancreatic cancer.

Jemal A, Siegel R, Ward E (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249PubMedCrossRef

ACS (2009) Cancer facts & figures 2009. American Cancer Society, Atlanta

Feldmann G, Maitra A (2008) Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn 10(2):111–122PubMedCrossRef

Maitra A, Kern SE, Hruban RH (2006) Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 20(2):211–226PubMedCrossRef

Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10(8):789–799PubMedCrossRef

Feldmann G, Rauenzahn S, Maitra A (2009) In vitro models of pancreatic cancer for translational oncology research. Expert Opin Drug Discov 4(4):429–443PubMedCrossRef

Feldmann G, Maitra A (2010) Molecular pathology of precursor lesions of pancreatic cancer. Pancreatic cancer. Springer, New York, pp 119–141

Moskaluk CA, Hruban RH, Kern SE (1997) p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57(11):2140–2143PubMed

Ruggeri BA, Huang L, Wood M (1998) Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 21(2):81–86PubMedCrossRef

10.

Asano T, Yao Y, Zhu J (2004) The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23(53):8571–8580PubMedCrossRef

11.

Schutte M, Hruban RH, Geradts J et al (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57(15):3126–3130PubMed

12.

Wilentz RE, Geradts J, Maynard R et al (1998) Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 58(20):4740–4744PubMed

13.

Bardeesy N, Aguirre AJ, Chu GC et al (2006) Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 103(15):5947–5952PubMedCrossRef

14.

Sharpless NE, Ramsey MR, Balasubramanian P et al (2004) The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 23(2):379–385PubMedCrossRef

15.

Maitra A, Adsay NV, Argani P et al (2003) Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 16(9):902–912PubMedCrossRef

16.

Zavoral M, Minarikova P, Zavada F, Salek C, Minarik M (2011) Molecular biology of pancreatic cancer. World J Gastroenterol 17(24):2897–2908PubMedCrossRef

17.

Genkinger JM, Spiegelman D, Anderson KE et al (2009) Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev 18:765–776PubMedCrossRef

18.

Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z (2011) Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 47(13):1928–1937PubMedCrossRef

19.

McKay CJ, Glen P, McMillan DC (2008) Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol 22(1):65–73PubMedCrossRef

20.

Lowenfels AB, Maisonneuve P, Lankisch PG (1999) Chronic pancreatitis and other risk factors for pancreatic cancer. Gastroenterol Clin North Am 28:673–685PubMedCrossRef

21.

Talamini G, Falconi M, Bassi C, Sartori N, Salvia R, Caldiron E, Frulloni L, Di Francesco V, Vaona B, Bovo P, Vantini I, Pederzoli P, Cavallini G (1999) Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 94:1253–1260PubMedCrossRef

22.

Lowenfels AB, Maisonneuve P (2005) Risk factors for pancreatic cancer. J Cell Biochem 95(4):649–656PubMedCrossRef

23.

Lowes N, Lerch MM, Charnley R et al (2002) Hereditary pancreatitis (HP) and the risk of pancreatic ductal adenocarcinoma (PDAC). Gut 50:A43CrossRef

24.

Lynch HT, Lanspa SJ, Fitzgibbons RJ Jr et al (1989) Familial pancreatic cancer (part 1): genetic pathology review. Nebr Med J 74:109–112PubMed

25.

Bartsch DK, Kress R, Sina-Frey M et al (2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110:902–906PubMedCrossRef

26.

Hemminki K, Li X (2003) Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 103:525–530PubMedCrossRef

27.

Tersmette AC, Petersen GM, Offerhaus GJ et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738–744PubMed

28.

Klein AP, Brune KA, Petersen GM et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634–2638PubMedCrossRef

29.

Rulyak SJ, Lowenfels AB, Maisonneuve P et al (2003) Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterol 124:1292–1299CrossRef

30.

Hruban RH, Adsay NV, Albores-Saavedra J et al (2006) Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66:95–106PubMedCrossRef

31.

Gopinathan A, Tuveson DA (2008) The use of GEM models for experimental cancer therapeutics. Dis Model Mech 1:83–86PubMedCrossRef

32.

Hingorani SR, Petricoin EF, Maitra A et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437–450PubMedCrossRef

33.

Hingorani SR, Wang L, Multani AS et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469–483PubMedCrossRef

34.

Guerra C, Schuhmacher AJ, Canamero M et al (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291–302PubMedCrossRef

35.

Schutte U, Bisht S, Brossart P, Feldmann G (2011) Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research. Expert Opin Drug Discov 6(1):33–48CrossRef

36.

Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890PubMedCrossRef

37.

Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899PubMedCrossRef

38.

Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Wilentz RE (2002) Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 118:194–201PubMedCrossRef

39.

Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JE (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307–311PubMedCrossRef

40.

Anderson KE, Johnson TW, Lazovich D, Folsom AR (2002) Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94:1168–1171PubMedCrossRef

41.

Schernhammer ES, Kang JH, Chan AT, Michaud DS, Skinner HG, Giovannucci E, Colditz GA, Fuchs CS (2004) A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96:22–28PubMedCrossRef

42.

Lara LF, Chari ST (2004) Does an aspirin a day keep pancreas cancer away? Gastroenterology 127:1002–1004PubMedCrossRef

43.

Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ (1999) The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinomas cells. Clin Cancer Res 5:119–127PubMed

44.

Sclabas GM, Uwagawa T, Schmidt C, Hess KR, Evans DB, Abbruzzese JL, Chiao PJ (2005) Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 12:2485–2490CrossRef

45.

Tan XL, Lombard KM, Bamlet WR et al (2011) Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case–control study. Cancer Prev Res 4(11):1835–1841CrossRef

46.

Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, Eibl G (2007) Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 67:7068–7071PubMedCrossRef

47.

Fendrich V, Chen NM, Neef M, Waldmann J, Bucholz M, Feldmann G, Slater EP, Maitra A, Bartsch DK (2010) The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 59:630–637PubMedCrossRef

48.

Hwang DM, Kundu JK, Shin JW, Lee JC, Lee HJ, Surh YJ (2007) cis-9,trans-11-conjugated linoleic acid down-regulates phorbol ester-induced NF-kappaB activation and subsequent COX-2 expression in hairless mouse skin by targeting IkappaB kinase and PI3K-Akt. Carcinogenesis 28:363–371PubMedCrossRef

49.

Fujioka S, Sclabas GM, Schmidt C et al (2003) Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 22:1365–1370PubMedCrossRef

50.

Dong QG, Sclabas GM, Fujioka S et al (2002) The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21:6510–6519PubMedCrossRef

51.

Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Sci 265:956–959CrossRef

52.

Mayo MW, Norris JL, Baldwin AS (2001) Ras regulation of NF-kB and apoptosis. Methods Enzymol 333:73–87PubMedCrossRef

53.

Mayo MW, Wang CY, Cogswell PC et al (1997) Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278:1812–1815PubMedCrossRef

54.

Reddy MK, Baskaran K, Molteni A (1995) Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 210:221–226PubMed

55.

Uemura H, Nakaigawa N, Ishiguro H, Kubota Y (2005) Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 5:307–323PubMedCrossRef

56.

Yoshiji H, Kuriyama S, Noguchi R, Fukui H (2004) Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr Cancer Drug Targets 4:555–567PubMedCrossRef

57.

Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352:179–184PubMedCrossRef

58.

Khurana V, Caldito G, Barkin JS (2008) Angiotensin converting enzyme inhibitors decrease the incidence of pancreatic cancer: a study of half a million US veterans. Eur J Cancer 1:S47–S48

59.

Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ (2007) Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 204:996–1005PubMedCrossRef

60.

Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA (2008) Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J Gastrointest Surg 12:57–66PubMedCrossRef

61.

Mohammed A, Janakiram NB, Li Q et al (2011) The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/⁺ transgenic mouse model. Cancer Prev Res 3:1417–1426CrossRef

62.

Johnson J, de Mejia EG (2011) Dietary factors and pancreatic cancer: the role of food bioactive compounds. Mol Nutr Food Res 55:58–73PubMedCrossRef

63.

Marti N, Mena P, Canovas J, Micol V, Saura D (2009) Vitamin C and the role of citrus juices as functional food. Nat Prod Commun 4:677–700PubMed

64.

Goel A, Kunnumakkara A, Aggarwal B (2008) Curcumin as “curecumin”: from kitchen to clinic. Biochem Pharmacol 75:787–809PubMedCrossRef

65.

Bar-Sela G, Epelbaum R, Schaffer M (2010) Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 17:190–197PubMedCrossRef

66.

Ujiki M, Ding X, Salabat M, Bentrem D et al (2006) Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol Cancer 5:76PubMedCrossRef

67.

Lee S, Ryu J, Lee K, Woo S et al (2008) Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett 259:39–49PubMedCrossRef

68.

Strouch M, Milam B, Melstrom L, McGill J et al (2009) The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Pancreas 38:409–415PubMedCrossRef

69.

Melstrom L, Salabat M, Ding X, Milam B et al (2008) Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cells. Pancreas 37:426–431PubMedCrossRef

70.

Zhang Y, Chen A, Li M, Chen C, Yao Q (2008) Ginkgo biloba extract kaempferol inhibits cell proliferation and induces apoptosis in pancreatic cancer cells. J Surg Res 148:17–23PubMedCrossRef

71.

Aghdassi A, Phillips P, Dudeja V, Dhaulakhandi D et al (2007) Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res 67:616–625PubMedCrossRef

72.

Li Y, Ahmed F, Ali S, Philip P et al (2005) Inactivation of nuclear factor κB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65:6934–6942PubMedCrossRef

73.

Banerjee S, Zhang Y, Ali S, Bhuiyan M et al (2005) Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65:9064–9072PubMedCrossRef

74.

Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar F (2006) Inhibition of nuclear factor κB activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer 118:1930–1936PubMedCrossRef

75.

Wang Z, Zhang Y, Li Y, Banerjee S et al (2006) Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 5:483–493PubMedCrossRef

76.

El-Rayes B, Ali S, Ali I, Philip P et al (2006) Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-κB. Cancer Res 66:10553–10559PubMedCrossRef

77.

Wang Z, Ahmad A, Banerjee S, Azmi A et al (2010) FoxM1 is a novel target of a natural agent of pancreatic cancer. Pharm Res 27:1159–1168PubMedCrossRef

78.

Bai H, Li H, Zhang W, Matkowskyj KA, Liao J, Srivastava SK, Yang GY (2011) Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice. Carcinogenesis 32:1689–1696PubMedCrossRef

79.

Tsao A, Kim E, Hong W (2004) Chemoprevention of cancer. CA Cancer J Clin 54:150–180PubMedCrossRef

Titel: Chemoprevention of pancreatic cancer—one step closer
verfasst von: Volker Fendrich
Publikationsdatum: 01.04.2012
Verlag: Springer-Verlag
Erschienen in: Langenbeck's Archives of Surgery / Ausgabe 4/2012
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-012-0916-x

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Discussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Ninety and still active in research

A critical appraisal of the hemodynamic signal driving liver regeneration

Molecular oxygen sensing: implications for visceral surgery

Targeting the vasculature of visceral tumors: novel insights and treatment perspectives

Bacterial immunotherapy of gastrointestinal tumors

Lynch syndrome: clinical, pathological, and genetic insights

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Hinter dieser Appendizitis steckte ein Erreger

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“